{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:00:26Z","timestamp":1771880426258,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.antiviral.2016.05.015","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T18:47:57Z","timestamp":1464720477000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Abacavir and cardiovascular disease: A critical look at the data"],"prefix":"10.1016","volume":"132","author":[{"given":"Josep M.","family":"Llibre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.antiviral.2016.05.015_bib1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/cid\/cir497","article-title":"Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort","volume":"53","author":"Baker","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"18","key":"10.1016\/j.antiviral.2016.05.015_bib2","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/QAD.0b013e32834d3cc3","article-title":"Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase","volume":"25","author":"Baum","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.antiviral.2016.05.015_bib3","doi-asserted-by":"crossref","first-page":"e59551","DOI":"10.1371\/journal.pone.0059551","article-title":"Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review","volume":"8","author":"Bavinger","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2016.05.015_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cir269","article-title":"Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era","volume":"53","author":"Bedimo","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2016.05.015_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","article-title":"Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects","volume":"51","author":"Brothers","year":"2009","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"issue":"18","key":"10.1016\/j.antiviral.2016.05.015_bib6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1097\/QAD.0b013e32831692e6","article-title":"HIV clinical trial design for antiretroviral development: moving forward","volume":"22","author":"Chan-Tack","year":"2008","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.antiviral.2016.05.015_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/QAD.0b013e328347fa16","article-title":"Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons","volume":"25","author":"Choi","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.antiviral.2016.05.015_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-010-0047-3","article-title":"Abacavir and cardiovascular risk: reviewing the evidence","volume":"7","author":"Costagliola","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"16","key":"10.1016\/j.antiviral.2016.05.015_bib9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data","volume":"25","author":"Cruciani","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.antiviral.2016.05.015_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/cid\/civ316","article-title":"Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population","volume":"61","author":"Desai","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2016.05.015_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/QAI.0b013e31826f993c","article-title":"No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis","volume":"61","author":"Ding","year":"2012","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.antiviral.2016.05.015_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31821d33a5","article-title":"Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec\u2019s public health insurance database","volume":"57","author":"Durand","year":"2011","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2016.05.015_bib13","series-title":"23TH Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Cardiovascular risk profile of abacavir and tenofovir independent of HIV infection","author":"Emerson","year":"2016"},{"key":"10.1016\/j.antiviral.2016.05.015_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/QAD.0b013e3283359253","article-title":"Kidney function and the risk of cardiovascular events in HIV-1-infected patients","volume":"24","author":"George","year":"2010","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.antiviral.2016.05.015_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.05.015_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proceed Roy. Soc. Med. - Lond."},{"issue":"15","key":"10.1016\/j.antiviral.2016.05.015_bib17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1097\/QAD.0b013e32832e7140","article-title":"Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients","volume":"23","author":"Hsue","year":"2009","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.antiviral.2016.05.015_bib18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/cid\/civ014","article-title":"Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care","volume":"60","author":"Klein","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"14","key":"10.1016\/j.antiviral.2016.05.015_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4","volume":"170","author":"Lang","year":"2010","journal-title":"Arch. Intern Med."},{"issue":"4","key":"10.1016\/j.antiviral.2016.05.015_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/QAI.0000000000000881","article-title":"Use of abacavir and risk of cardiovascular disease among HIV-infected individuals","volume":"71","author":"Marcus","year":"2016","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"issue":"10","key":"10.1016\/j.antiviral.2016.05.015_bib21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial","volume":"49","author":"Martin","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"17","key":"10.1016\/j.antiviral.2016.05.015_bib22","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/QAD.0b013e32833f147f","article-title":"Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial","volume":"24","author":"Martin","year":"2010","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.antiviral.2016.05.015_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11904-015-0284-6","article-title":"Risk of cardiovascular disease in an aging HIV population: where are we now?","volume":"12","author":"Martin-Iguacel","year":"2015","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"2","key":"10.1016\/j.antiviral.2016.05.015_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1468-1293.2009.00751.x","article-title":"Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study","volume":"11","author":"Obel","year":"2010","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2016.05.015_bib25","series-title":"CROI","article-title":"Abacavir use and risk for myocardial infarction in the NA-ACCORD","author":"Palella","year":"2015"},{"issue":"7","key":"10.1016\/j.antiviral.2016.05.015_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/ciq244","article-title":"No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001\/ALLRT","volume":"52","author":"Ribaudo","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2016.05.015_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/cid\/cit196","article-title":"Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons","volume":"57","author":"Rotger","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"9622","key":"10.1016\/j.antiviral.2016.05.015_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: a:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.antiviral.2016.05.015_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","article-title":"Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration","volume":"14","author":"Sabin","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.antiviral.2016.05.015_bib30","series-title":"23TH Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Abacavir (ABC) use and risk of recurrent myocardial infarction (MI)","author":"Sabin","year":"2016"},{"issue":"8","key":"10.1016\/j.antiviral.2016.05.015_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/infdis\/jir509","article-title":"Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy","volume":"204","author":"Satchell","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.015_bib32","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","author":"Sax","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.antiviral.2016.05.015_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/QAI.0b013e3181f4b752","article-title":"Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system","volume":"55","author":"Triant","year":"2010","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2016.05.015_bib34","unstructured":"Triumeq. Highlights of prescribing information. US Food and Drug Administration. Available at: http:\/\/www.fda.gov\/default.htm. Accessed: April 6, 2016."},{"key":"10.1016\/j.antiviral.2016.05.015_bib35","unstructured":"Triumeq. Summary of product characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/ema\/. Accessed April 6, 2016."},{"key":"10.1016\/j.antiviral.2016.05.015_bib36","doi-asserted-by":"crossref","unstructured":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22(14):F17\u2013F24.","DOI":"10.1097\/QAD.0b013e32830fe35e"},{"key":"10.1016\/j.antiviral.2016.05.015_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000000662","article-title":"The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study","author":"Young","year":"2015","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T02:39:54Z","timestamp":1567996794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216302959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":37,"alternative-id":["S0166354216302959"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abacavir and cardiovascular disease: A critical look at the data","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}